AlphAIAlphAI — Financial news for AI agents
uk.investing.comAUG 242 min read$SKWD

Piper Sandler reiterates Skyward Specialty stock rating after CFO news

Piper Sandler maintained an Overweight rating and $72.00 price target for Skyward Specialty Insurance Group (SKWD) after its CFO announced retirement. The firm views the retirement as planned and does not see it as a negative. SKWD reported Q2 2026 earnings of $1.30 per share, beating estimates, with revenue of $489.53 million. The stock trades at $58.23 with a P/E ratio of 14.41 and a PEG ratio of 0.37.

Original reporting
uk.investing.com
Published Aug 24, 2026, 2:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 5:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SKWD
Neutral
medium confidence
Mentioned
$SKWD
Relevance
4/10
AlphAI data visualization · based on uk.investing.com
Decision brief

The 30-second read

$SKWDNeutralLow
01

Why it matters

Analyst rating reiteration provides modest guidance but adds little new information.

02

Market read

The piece offers limited trading relevance; mainly a reminder of existing analyst stance.

03

What to watch

Potential hidden risks from the soft insurance market and the CFO transition could affect execution.

Relevance 4/10Novelty 2/10Timing: post CFO retirement announcement

Background

The article repeats Piper Sandler's analyst coverage after a CFO retirement announcement made earlier in the week.

Company-level read

Ticker impact

$SKWDNeutralMedium confidence
Context

Piper Sandler reiterated Overweight rating and $72 price target after the CFO retirement announcement.

Expected impact

Limited, potential slight price appreciation if investors follow the rating.

Evidence & confidence

Rating reiteration is a follow‑up to a previously disclosed CFO retirement; impact is incremental.

Market effects

Sector

Reinforces positive view on specialty insurance sector amid soft market conditions.

Regional

Limited to US specialty insurers; no broader regional effect.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Investors may view the reiteration as a sign of limited upside and could stay on the sidelines.

Key entities

  • Company
    Skyward Specialty Insurance Group

    Specialty commercial insurer listed on NASDAQ.

  • Research Firm
    Piper Sandler

    Equity research analyst covering SKWD.

Read at source← All news

Related articles

AUG 5
$SKWDMed

Skyward Specialty grows agriculture and A&H as it trims property and captives

Skyward Specialty Insurance Group reported Q2 2026 combined ratio of 89.5% and diluted operating EPS of $1.30, up 46% YoY. Gross written premiums rose 13.3% to $740.6M pro forma, with net written premiums at $485.6M. Management grew agriculture and A&H while reducing property and captives; Apollo acquisition closed Jan 1. Book value per share rose to $28.55 and it repurchased 223k shares for $9.7M.

insurancebusinessmag.com6 min
AUG 4
$SKWDMed

Skyward Group Reports Second Quarter 2026 Results

Skyward Specialty Insurance Group, Inc. (SKWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Skyward Group Reports Second Quarter 2026 Results Houston, TX – August 4, 2026 – Skyward Specialty Insurance Group, Inc. (Nasdaq: SKWD) (“Skyward Group” or the “Company”) today reported second quarter 2026 results. Summary Financial Data ($ in thousands, except per s

SEC EDGAR 8-K6 min
OCT 24
$AZNHigh

A lung cancer trial found 21.1 months’ median survival with two drugs, versus 12.7 with one.

AstraZeneca's trial showed IMFINZI plus tarlatamab-dlle improved median survival to 21.1 months vs. 12.7 months with IMFINZI alone in extensive-stage small cell lung cancer. The combination reduced death risk by 58% and progression risk by 66%. Results were consistent across subgroups, including brain metastases. AstraZeneca aims to redefine treatment standards. Data presented at ESMO Congress 2026.

stocktitan.net3 min
OCT 24
$AMGNHigh

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

Amgen (AMGN) announced that IMDELLTRA® combined with AstraZeneca's IMFINZI® reduced the risk of death by 58% in extensive stage small cell lung cancer (ES-SCLC) patients. Median overall survival increased to 21.1 months from 12.7 months with IMFINZI alone. The Phase 3 DeLLphi-305 study results were presented at ESMO Congress 2026 and published in The New England Journal of Medicine.

prnewswire.com2 min